Departed
Mark DiPaolo
Director
INVA ·
Innoviva, Inc.
On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.
INVA
Innoviva, Inc.
Saved in this browser
Ready 8-Ks
7
Latest filing
May 18, 2026 20:21 UTC
Top materiality
0.75
Event mix
earnings ×4 · other ×2 · leadership ×1
Sentiment
4 pos · 0 neg · 3 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for INVA
Highest-materiality recent filing
Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M
- Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).
- Net product sales $41.4M (+37% YoY); US sales $34.2M led by GIAPREZA $19.7M, XACDURO $11.6M.
-
Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M
Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).
-
Innoviva Q4 revenue up 25% to $114.6M; net income $164.2M; NUZOLVENCE approved
Full year 2025 revenue $411.3M (+15% YoY); net income $271.2M ($4.02 basic EPS).
-
Innoviva Q3: Revenue $107.8M (+20% YoY), Net Income $89.9M, $125M Buyback
Total revenue $107.8M (+20% YoY); GSK royalty $63.4M; net product sales $47.3M (U.S. $29.9M, +52% YoY).
-
Innoviva Q2 2025 net income $63.7M; product sales up 54% YoY; zoliflodacin PDUFA Dec 15
Q2 2025 net income $63.7M ($1.01 basic EPS) vs net loss of $34.7M in Q2 2024.
Executive changes
Appointed
Josephine Linden
Director
INVA ·
Innoviva, Inc.
On May 18, 2026, following the resignations of Messrs. Small and DiPaolo, the Board elected Josephine Linden to serve as a member of the Board of Directors (the “Linden Effective Date”).
Departed
Derek Small
Director
INVA ·
Innoviva, Inc.
On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.75 · Most common event earnings